Abstract: The present invention relates to chemical processes useful in the manufacture of the compound 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (the active entity within AZD0530), to intermediates useful in the manufacture of that compound and to processes for the manufacture of those intermediates. The invention also relates to particular crystalline forms of that compound such as a difumarate salt and a trihydrate and to pharmaceutical compositions containing such crystalline forms.

Abstract: There is provided processes for the preparation of various compounds, including compounds of formulae I, IV and VII, or salts and/or solvates thereof, which compounds are useful intermediates in the synthesis of certain oxabispidines having antiarrhythmic activity, such as compounds of formula XI wherein R1?, R15?, R16?, R18? and D have meanings given in the description.

Abstract: The invention provides compounds of formula (I): wherein: X is CH2, O, S(O)2 or NR10; Y is a bond, CH2, NR35, CH2NH, CH2NHC(O), CH(OH), CH(NHCOR33), CH(NHSO2R34), CH2O or CH2S; Z is C(O), or when Y is a bond Z can also be S(O)2; R1 is optionally substituted aryl, optionally substituted heterocyclyl or C4-6 cycloalkyl fused to a benzene ring; and R2, R3, R4, R5, R6, R7 and R8, R9, R10, R32, R33, R34 and R35 are as defined herein; are modulators of chemokine (especially CCR3) activity (for use in, for example, treating asthma). The invention also provides a process for making 4-(3,4-dichlorophenoxy)piperidine, which is useful as an intermediate for making certain compounds of the invention.

Abstract: The present invention relates to chemical processes useful in the manufacture of the compound 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (the active entity within AZD0530), to intermediates useful in the manufacture of that compound and to processes for the manufacture of those intermediates. The invention also relates to particular crystalline forms of that compound such as a difumarate salt and a trihydrate and to pharmaceutical compositions containing such crystalline forms.

Abstract: An expected wait time calculation system generates an expected wait time value representing a time duration expected to elapse before a subject client is connected to a resource for servicing. The expected wait time calculation system comprises an interface to a work force management system for obtaining an indicator of a quantity of resources available for servicing clients. An interface to a queuing system obtains an indicator of a queue position of the subject client. A FIFO array stores a plurality of measured time intervals, each representing a time period between two successive resource queue decrement events. The measured time intervals may be stored in a chronological order. An average time interval, or rate, calculator determines an average time interval by calculating an average of a selected quantity of those most recently measured time intervals from the FIFO array or a rate by dividing a unit of time by the average time interval.

Abstract: The invention provides anhydrous and hydrated forms of sodium salt of N-[[4-(3,4-dichlorophenoxy)[1,4?-bipiperidin]-1?-yl]carbonyl]-4-methyl-benzenesulfonamide and crystalline forms of N-[[4-(3,4-dichlorophenoxy)[1,4?-bipiperidin]-1?-yl]carbonyl]-4-methyl-benzenesulfonamide; and such compounds are modulators of chemokine (especially CCR3) activity and are especially useful for treating asthma and/or rhinitis.

Abstract: A salt of substituted or unsubstituted methylene bisphosphonic acid of formula I wherein X1 and X2 are both chlorine or one of X1 and X2 is hydrogen and one is chlorine and the salt is selected from the group consisting of a C1-16 straight or branched primary, secondary or tertiary alkyl amine salt, an aralkyl amine salt, and a basic N-containing heterocycle salt. The salts are used for preparing pharmaceutically relevant compounds.

Abstract: The present invention concerns a process for preparing 4-(hydroxy)-[1,4?]bipiperidinyl-1?-carboxylic acid tert-butyl ester, comprising hydrogenating a mixture of 4-hydroxypiperidine and 1-tert-butoxycarbonyl-4-piperidone in a suitable solvent, in the presence of a suitable catalyst and at a suitable pressure.

Abstract: The invention provides compounds of formula (I):[Chemical formula should be inserted here. Please see paper copy]wherein: X is CH2, O, S(O)2 or NR10; Y is a bond, CH2, NR35, CH2NH, CH2NHC(O), CH(OH), CH(NHCOR33), CH(NHSO2R34), CH2O or CH2S; Z is C(O), or when Y is a bond Z can also be S(O)2; R1 is optionally substituted aryl, optionally substituted heterocyclyl or C4-6 cycloalkyl fused to a benzene ring; and R2, R3, R4, R5, R6, R7 and R8, R9, R10, R32, R33, R34 and R35 are as defined herein; are modulators of chemokine (especially CCR3) activity (for use in, for example, treating asthma). The invention also provides a process for making 4-(3,4-dichlorophenoxy)piperidine, which is useful as an intermediate for making certain compounds of the invention.

Abstract: The present invention concerns a process for preparing 4-(hydroxy)-[1,4′]bipiperidinyl-1′-carboxylic acid tert-butyl ester, comprising hydrogenating a mixture of 4-hydroxypiperidine and 1-tert-butoxycarbonyl-4-piperidone in a suitable solvent, in the presence of a suitable catalyst and at a suitable pressure.

Abstract: A process for the preparation of salts of substituted or unsubstituted methylene bisphosphonic acids by hydrolysing the corresponding acid ester with hydrochloric acid, removing water from the acid azeotropically prior to addition of an amine or a base to produce the resultant salt in good yield.

Abstract: A process for the preparation of salts of substituted or unsubstituted methylene bisphosphonic acids by hydrolysing the corresponding acid ester with hydrochloric acid, removing water from the acid azeotropically prior to addition of an amine or a base to produce the resultant salt in good yield.